Furthermore, plasma NfL levels could be a promising biomarker for distinguishing neurodegeneration and cognitive decline due to Alzheimer’s disease from other conditions that potentially cause cognitive impairment in the prodromal stages [13]. The gene discussed is NEFL; the disease is early-onset autosomal dominant Alzheimer disease.